ライフサイエンスコーパス: multiple organ

1 tumor suppressor and has beneficial roles in multiple organs.

2 inflammatory responses and hypoxic injury of multiple organs.

3 of wildlings affect the immune landscape of multiple organs.

4 ffers the potential to detect AL deposits in multiple organs.

5 the ZnT10 gene leads to hypermanganesemia in multiple organs.

6 roteome that is perfusable and shared across multiple organs.

7 vere dose-dependent inflammatory response in multiple organs.

8 tion between different endocrine systems and multiple organs.

9 gulator of tissue repair and regeneration in multiple organs.

10 obesity treatment due to systemic effects on multiple organs.

11 r and cellular networks over time and across multiple organs.

12 ith time, and certain clones were present in multiple organs.

13 , and on pericytes and perivascular cells in multiple organs.

14 ficiency, leads to substrate accumulation in multiple organs.

15 in cilia and is required for ciliogenesis in multiple organs.

16 is, anemia, and VWF-positive microthrombi in multiple organs.

17 2, a known molecular marker of pericytes in multiple organs.

18 was associated with greater viral burden in multiple organs.

19 ystal formation and functional impairment of multiple organs.

20 osis is an inflammatory disease that affects multiple organs.

21 idence of systemic dissemination of virus to multiple organs.

22 y massive accumulation of transformed DCs in multiple organs.

23 onic inflammation or tumors, often affecting multiple organs.

24 ing elevated glycosaminoglycans in blood and multiple organs.

25 ix, has demonstrated antifibrotic effects in multiple organs.

26 ome causing connective tissue disruptions in multiple organs.

27 pic autosomal recessive ciliopathy affecting multiple organs.

28 autoimmunity with T and B cell responses to multiple organs.

29 ular function and reduced tissue toxicity in multiple organs.

30 and plays an important role in carcinomas of multiple organs.

31 mmune complexes resulting in inflammation of multiple organs.

32 nant syndrome that causes tumor formation in multiple organs.

33 ssues, (ii) extends duration of silencing in multiple organs and (iii) protects siRNAs from 5-to-3 ex

34 ivity is critical for tissue regeneration in multiple organs and contexts.

35 also known as uremic toxins), dysfunction of multiple organs and dysbiosis of the gut microbiota.

36 h, neuroimmune interactions are found across multiple organs and have recently emerged as important r

37 and temporal differences in CMA activity in multiple organs and in response to stress.

38 plays a critical role in the development of multiple organs and is typically downregulated after dev

39 gE-dependent immune response that can affect multiple organs and lead to life-threatening complicatio

40 an explosion of cell type definitions across multiple organs and organisms.

41 Incorporation of human microsomes from multiple organs and selected supersomes of single cytoch

42 omal subunit, increased metastatic growth in multiple organs and selectively enhanced translation of

43 cate DDIT4/IFRD1 in governing paligenosis in multiple organs and species.

44 was sufficient to induce severe fibrosis in multiple organs and steatohepatosis, which was dependent

45 factors operating during the development of multiple organs and structures.

46 ived cells form the lymphatic endothelium of multiple organs and tissues, with a more restricted cont

47 asis and for the development and function of multiple organs and tissues.

48 and observed markedly decreased Mn levels in multiple organs and whole blood of both mouse models.

49 l alphaKlotho levels, decreased pathology of multiple organs, and improved fertility compared to kl/k

50 CMV immunopathology, enhances MCMV burden in multiple organs, and suppresses MCMV-specific T cell mem

51 re immunopathology, enhanced viral burden in multiple organs, and suppression of MCMV-specific T cell

52 ility, epilepsy, coarse facial features, and multiple organ anomalies.

53 ome characterised by a unique combination of multiple organ anomalies.

54 Os) play crucial roles in the development of multiple organs as well as the survival of adult stem ce

55 lting mice showed low heteroplasmy levels in multiple organs at adult age, normal histology and ferti

56 ially accumulate in the periphery and induce multiple organ-autoimmune-lesions.

57 uced a cohort of genes regulated by MIST1 in multiple organs but did not affect PC function.

58 al roles in the formation and homeostasis of multiple organs, but direct experiments to address the r

59 inical management in Li-Fraumeni syndrome, a multiple-organ cancer predisposition condition, are limi

60 t SGK1 inhibition aggravates the severity of multiple organ damage and enhances the inflammatory resp

61 metinib attenuates systemic inflammation and multiple organ damage in a clinically relevant model of

62 efects in clearing dying cells, which led to multiple organ damage indicative of immune dysfunction.

63 nished vascular inflammation, attenuation of multiple organ damage, and survival advantage in a mouse

64 cation of systemic infection associated with multiple organ damage.

65 s of function of SHP2 cause 2 disorders with multiple organ defects: Noonan syndrome (NS) and NS with

66 ropsy based on histopathologic evaluation of multiple organs demonstrating accumulation of mucopolysa

67 Obesity increases susceptibility to multiple organ disorders, however, underlying mechanisms

68 2 activation, we show that ILC2s appeared in multiple organs during late gestation like tissue macrop

69 hose due to traumatic brain injury (52%) and multiple organ dysfunction (45%).

70 enine 3-monooxygenase (KMO) protects against multiple organ dysfunction (MODS) in experimental acute

71 ts that resulted in significantly attenuated multiple organ dysfunction and reduced vasopressor and f

72 clinical features, including sepsis-related multiple organ dysfunction as well as the pathophysiolog

73 eperfusion resulting from S/R contributes to multiple organ dysfunction in trauma patients.

74 days on mechanical ventilator, and Marshall Multiple Organ Dysfunction score between hypotensive and

75 organ dysfunction, reflected in a cumulative Multiple Organ Dysfunction Score greater than 25, and pa

76 The Multiple Organ Dysfunction Score is a simple organ-based

77 l the other scores with the exception of the Multiple Organ Dysfunction Score, which was significantl

78 II, Sequential Organ Failure Assessment, and Multiple Organ Dysfunction Scores gave area under the re

79 II, Sequential Organ Failure Assessment, and Multiple Organ Dysfunction Scores were all applied to pa

80 sociation between plasma acetylcarnitine and multiple organ dysfunction severity, blood culture posit

81 clinician type for either identification of multiple organ dysfunction syndrome (80.2% vs 78.2% vs 8

82 = 0.57) or prediction of new or progressive multiple organ dysfunction syndrome (84.8% vs 82.8% vs 8

83 dentified as a target for acute pancreatitis multiple organ dysfunction syndrome (AP-MODS); a devasta

84 t reduce the incidence of new or progressive multiple organ dysfunction syndrome (including mortality

85 of sterile inflammation leading to systemic multiple organ dysfunction syndrome (MODS) and death.

86 The development of multiple organ dysfunction syndrome (MODS) following inf

87 te lung injury (ALI) is a major component of multiple organ dysfunction syndrome (MODS) following pul

88 Severe bacterial infection can cause sepsis, multiple organ dysfunction syndrome (MODS), and death.

89 storm" can lead to poor outcomes, including Multiple Organ Dysfunction Syndrome (MODS).

90 of its relationship with the development of multiple organ dysfunction syndrome (MODS).

91 events were cerebrovascular accident (n=1), multiple organ dysfunction syndrome (n=2), pulmonary emb

92 PICU clinicians correctly identified multiple organ dysfunction syndrome and predicted new or

93 mes were clinicians' accuracy at identifying multiple organ dysfunction syndrome and predicting new o

94 ignificant differences in new or progressive multiple organ dysfunction syndrome between fresh (147 o

95 systemic inflammatory response syndrome and multiple organ dysfunction syndrome is poorly understood

96 18.7%) at enrollment, and new or progressive multiple organ dysfunction syndrome occurred in 39 (8.2%

97 itive predictive value of new or progressive multiple organ dysfunction syndrome prediction was just

98 tive predictive value for new or progressive multiple organ dysfunction syndrome prediction was just

99 ive likelihood ratios for new or progressive multiple organ dysfunction syndrome prediction were 3.0

100 t of systemic inflammatory response syndrome/multiple organ dysfunction syndrome that is causal to cr

101 ome, compared to the objective assessment of multiple organ dysfunction syndrome using Proulx criteri

102 Multiple organ dysfunction syndrome was present in 89 pa

103 Clinicians correctly identified multiple organ dysfunction syndrome with 79.9% accuracy

104 on syndrome and predicted new or progressive multiple organ dysfunction syndrome with 80% accuracy.

105 reatening illness characterized by shock and multiple organ dysfunction syndrome, are discussed.

106 n syndrome and predicting new or progressive multiple organ dysfunction syndrome, compared to the obj

107 imary outcome measure was new or progressive multiple organ dysfunction syndrome, measured for 28 day

108 s, general physical health deterioration and multiple organ dysfunction syndrome, pneumonia, pneumoni

109 8% of patients developed new or progressive multiple organ dysfunction syndrome, so accuracy was lar

110 l outcomes were associated with irreversible multiple organ dysfunction syndrome.

111 t of systemic inflammatory response syndrome/multiple organ dysfunction syndrome.

112 iction and development of new or progressive multiple organ dysfunction syndrome.

113 terized by fever, gastrointestinal signs and multiple organ dysfunction syndrome.

114 Profile 2 (15%) was characterized by multiple organ dysfunction with evidence of coagulopathy

115 ld decrease hospital length of stay, prevent multiple organ dysfunction, and reduce subsequent ICU in

116 ciations between brain dysfunction, systemic multiple organ dysfunction, environmental stimuli that e

117 ogresses towards end stage renal failure and multiple organ dysfunction.

118 lymph node histopathology, and often deadly multiple organ dysfunction.

119 es during septic shock and may contribute to multiple organ dysfunction.

120 ure, acute respiratory distress syndrome, or multiple organ dysfunction; and direct tissue injury (n

121 Sepsis causes multiple-organ dysfunction including pancreatic injury,

122 ere more likely to have prolonged (>=7 days) multiple-organ dysfunction syndrome (30.3% vs 8.6%; P =

123 The clinical assessment of multiple organ dysfunctions at early stages is recognize

124 by overproduction of type 1 IFN that causes multiple organ dysfunctions.

125 r adventitial 'cuffs' are conserved sites in multiple organs, enriched for these tissue-resident lymp

126 died within 14 days, primarily of refractory multiple organ failure (62%).

127 ent; p = 0.004), especially in patients with multiple organ failure (acute-on-chronic liver failure g

128 ions that include fever and rash, as well as multiple organ failure (liver, kidney, lungs, and/or hea

129 without new onset thrombocytopenia but with multiple organ failure (MOF).

130 nfidence interval (CI): 0.09-0.55; P <0.01), multiple organ failure (OR = 0.15; 95% CI: 0.04-0.62; P

131 erative intensive care stay (P = 0.014), and multiple organ failure (P < 0.001); operation before 200

132 septic shock and thrombocytopenia-associated multiple organ failure (TAMOF), and in those without new

133 rsus-host disease, and the patient died from multiple organ failure 4 months after transplantation.

134 tients who have a hematologic malignancy and multiple organ failure admitted to the ICU.

135 Between causes of death, multiple organ failure and brain death affected respecti

136 ciated with severe disease pathology such as multiple organ failure and cerebral malaria.

137 uncontrolled immune activation resulting in multiple organ failure and death.

138 re to develop sepsis, which may culminate in multiple organ failure and death.

139 nd chemokine interactions, which might limit multiple organ failure and decrease mortality in hemorrh

140 Multiple organ failure and early cardiogenic shock seem

141 bundles has fortunately led to a decline in multiple organ failure and in-hospital mortality.

142 nthetic RvD1 on resuscitation attenuated the multiple organ failure associated with HS by a mechanism

143 Hemorrhagic shock often progresses to multiple organ failure despite conventional resuscitatio

144 Cause of death was neurologic in 60.0% and multiple organ failure in 34.3% of pediatric acute respi

145 e Staphylococcus haemolyticus, septic shock, multiple organ failure including acute respiratory distr

146 deteriorate and within 3 weeks had developed multiple organ failure requiring ventilation, haemofiltr

147 ntially supportive with management of severe multiple organ failure resulting from immune-mediated ce

148 red blood cells within 24 hours, and Denver multiple organ failure score at 72 hours as independent

149 005), greater organ failure severity (Denver multiple organ failure score, 3.5 +/- 2.4 vs 0.8 +/- 1.1

150 Our results suggest that multiple organ failure should not be used as a criterion

151 He was in a septic shock with multiple organ failure up on presentation to emergency r

152 exchange use in thrombocytopenia-associated multiple organ failure was associated with a decrease in

153 e, hepatic failure, and hemodynamic failure; multiple organ failure was defined as failure of two or

154 Multiple organ failure was inversely associated with lon

155 ree distinct subphenotypes of CA; those with multiple organ failure were associated with a significan

156 in children with thrombocytopenia-associated multiple organ failure who received therapeutic plasma e

157 cessive activation leads to cytokine storms, multiple organ failure, and even death.

158 cations, but mostly due to the occurrence of multiple organ failure, and occurred after a median time

159 species colonization at multiple sites, and multiple organ failure, empirical treatment with micafun

160 ccompanied by diarrhea and often followed by multiple organ failure, especially of the respiratory an

161 uired sepsis, multiple Candida colonization, multiple organ failure, exposed to broad-spectrum antiba

162 nt patients, complicated by septic shock and multiple organ failure, including acute renal injury and

163 Male sex, multiple organ failure, increasing percentage of pancrea

164 included respiratory infection, sepsis, and multiple organ failure, length of stay and mortality; ad

165 composite of major complications (new-onset multiple organ failure, new-onset systemic dysfunction,

166 ulnerable obese population, evolved toward a multiple organ failure, required prolonged mechanical ve

167 ardiovascular, renal and liver injury or/and multiple organ failure, suggesting a spread of the SARS-

168 extracorporeal life support while in severe multiple organ failure.

169 nduce uncontrolled systemic inflammation and multiple organ failure.

170 a due to excessive systemic inflammation and multiple organ failure.

171 rfusion, systemic inflammatory response, and multiple organ failure.

172 sponse to infection that often culminates in multiple organ failure.

173 ents with acute-on-chronic liver failure and multiple organ failure.

174 Most deaths occurred early after multiple organ failure.

175 ic ischemia, and the patient rapidly died of multiple organ failure.

176 nduces hyperinflammation, ultimately causing multiple organ failure.

177 er OHCA, cyclosporine does not prevent early multiple organ failure.

178 of systemic inflammatory response underlying multiple organ failure.

179 can be challenging to manage and can lead to multiple organ failure.

180 n previously shown to be more susceptible to multiple organ failure.

181 atio, 0.15; 95% CI, 0.03-0.60) and new-onset multiple-organ failure (15.6% vs 39.1%; P = .008; risk r

182 h increased risk of cardiovascular death and multiple-organ failure (adjusted hazard ratio, 2.07 [1.3

183 rimarily driven by cardiovascular causes and multiple-organ failure, and may thus identify a vulnerab

184 econdary conditions such as septic shock and multiple-organ failure.

185 ndin-based 3D cultures, Lgr5 stem cells from multiple organs form ever-expanding epithelial organoids

186 serum, implicating that IL-18BP may protect multiple organs from radiation-induced inflammation and

187 Aging can cause multiple organ function attenuations, leading to the occ

188 basic cellular mechanisms and necessary for multiple organ function.

189 he identification of a putative syntelog for multiple organ gigantism in legumes.

190 002 to 2016 after excluding those listed for multiple organs, hepatocellular carcinoma, or living don

191 significant reduction in leukemia burden in multiple organs in 2 distinct mouse models of T-ALL and

192 rdio-cerebrovascular complications affecting multiple organs in individuals with prediabetes.

193 e techniques, viral RNA has been detected in multiple organs in the body, including the kidney.

194 up 2 innate lymphoid cells (ILC2s) reside in multiple organs in the body, where they play roles in im

195 athway is essential for the morphogenesis of multiple organs in the digestive system.

196 etic disease that affects the development of multiple organs in the human body.

197 provide signals critical for T-ALL growth in multiple organs in vivo and implicate tumor-associated m

198 ied as a source of MSC precursors in vivo in multiple organs, in response to injury or during homeost

199 a subset of CD11b(+)CD11c(+)MHCII(+) MNPs in multiple organs including adipose tissues.

200 is an uncommon autoimmune disease involving multiple organs including eyes such as conjunctivitis, s

201 Palpha), a transcription factor expressed in multiple organs including the bone marrow.

202 es cell fate selection during development in multiple organs including the lung.

203 rombophilia involving large blood vessels in multiple organs, including liver, lung, spleen, and kidn

204 drome, characterized by tumor development in multiple organs, including renal angiomyolipoma.

205 The axolotl can regenerate multiple organs, including the brain.

206 p malformations and hypoplasia or aplasia of multiple organs, including the craniofacial skeleton, ea

207 ammatory, fibrotic and neoplastic disease in multiple organs, including the detection and quantificat

208 mune activation resulting in inflammation of multiple organs, including the gastrointestinal tract, l

209 mmon of the microdeletion syndromes, affects multiple organs, including the heart, the nervous system

210 Flow cytometric analysis of multiple organs, including the kidney, liver, lung, lymp

211 Multiple organs, including the lacrimal glands (LGs), ar

212 Fibrosis in multiple organs, including the liver, kidney, and lung,

213 cial for the development and size control of multiple organs, including the liver.

214 lammation and disrupt the normal function of multiple organs, including the lungs.

215 ed in the pathogenesis of diseases affecting multiple organs, including the neural tube, kidney, and

216 erefore may mitigate/treat radiation-induced multiple organ injuries and increase animal survival wit

217 Artesunate attenuated the multiple organ injury and dysfunction caused by HS.

218 Trametinib also attenuated multiple organ injury as determined by serum creatinine,

219 RecAP prevents multiple organ injury by reducing receptor expression an

220 e (SCD) leads to a chronic vasculopathy with multiple organ involvement.

221 hrombocytopenia and acute renal failure with multiple organ involvement.

222 umorigenesis has been extensively studied in multiple organs, its role in ovarian follicle developmen

223 cterized by somatic stem cell dysfunction in multiple organs leading to BM failure and other pleiotro

224 mice as a single pool, and their delivery to multiple organs (liver, spleen, brain, lung, heart, kidn

225 py, diffuse iron deposition was occurring in multiple organs, markedly in the heart and liver.

226 lethal disease that impairs the function of multiple organs, mostly the lungs.

227 sequestration of parasitized erythrocytes in multiple organs obtained during a prospective series of

228 ericytes and vascular smooth muscle cells in multiple organs of adult mouse.

229 GSNOR activity was increased in plasma and multiple organs of mice, including brain in particular.

230 firmed the presence of mEV71 in the sera and multiple organs of mice.

231 isease characterized by fibrosis of skin and multiple organs of which the pathogenesis is poorly unde

232 and mitochondrial DNA mutations that affect multiple organs, often including the central and periphe

233 Regions of interest were drawn around multiple organs on the CT scan and copied to the PET sca

234 -threatening autoimmune disorder, leading to multiple organ pathologies and kidney destruction.

235 ity to quantify anatomical phenotypes across multiple organs provides the opportunity to assess their

236 epatitis cirrhosis (n = 118) after excluding multiple-organ re-LT and individuals with hepatocellular

237 and/or lung recipients, and higher in other/multiple organ recipients (aIRR = 2.45).

238 lated insulin resistance (IR) may develop in multiple organs, representing various etiologies for car

239 A postmortem, virological analysis of multiple organs, such as the kidneys (epithelial cells i

240 ures of encephalopathy (Glasgow Coma Scale), multiple organ system function (Sequential Organ Failure

241 ordinated physiological deterioration across multiple organ systems (e.g., pulmonary, periodontal, ca

242 It involves multiple organ systems and can cause life-threatening di

243 demonstrates high diagnostic accuracy across multiple organ systems and is comparable to experienced

244 X activity has been shown to be essential in multiple organ systems and to have important translation

245 In pleiotropic diseases, multiple organ systems are affected causing a variety of

246 and characterized by abnormalities spanning multiple organ systems ascertained with variable clinica

247 , the additive effect of DDAH1 expression in multiple organ systems determines plasma ADMA concentrat

248 al science point to potential targets across multiple organ systems for early intervention to improve

249 rden of grade 2-4 health conditions involved multiple organ systems for survivors treated on protocol

250 us genes on chromosome 15q11-q13 and affects multiple organ systems in the body, including the nervou

251 causes a complex clinical syndrome affecting multiple organ systems including left heart, brain, kidn

252 Multiple organ systems require epithelial barriers for n

253 -art, multimodality perspective spanning the multiple organ systems that contribute to cardiometaboli

254 have consequences for sex differences across multiple organ systems that, in part, share common patho

255 ing system that integrates measurements from multiple organ systems using a high-resolution database

256 Systemic lupus erythematosus (SLE) impacts multiple organ systems, although the causes of many indi

257 ences of PH and right-sided heart failure on multiple organ systems, focusing on self-perpetuating pa

258 ased risk of hospitalization for diseases of multiple organ systems, including certain diseases of th

259 oices and lead to cardiovascular events span multiple organ systems, including the central nervous, e

260 s rapidly activated in response to stress in multiple organ systems, including the kidney.

261 important upstream and downstream effects on multiple organ systems, particularly with respect to the

262 both chronic immunologic disorders involving multiple organ systems, reports about association of dis

263 pleiotropic functions in the development of multiple organ systems, which has broad implications for

264 r systemic or tissue-specific effects across multiple organ systems, with mild to severe symptoms, an

265 des of ischemia-reperfusion injury (I/RI) to multiple organ systems.

266 Organismal phenotypes frequently involve multiple organ systems.

267 distinctive facial features, and deficits in multiple organ systems.

268 This paradigm has pervasive benefits on multiple organ systems.

269 ne function, wound repair, and protection of multiple organ systems.

270 ,5)-bisphosphate (PI(3,5)P2) is essential in multiple organ systems.

271 AI-1) have been shown to promote fibrosis in multiple organ systems.

272 percytokinemia and immune-mediated injury of multiple organ systems.

273 essors to accelerate biological aging across multiple organ systems.

274 synchronisation of internal processes across multiple organ systems.

275 ling those observed in human patients across multiple organ systems.

276 d generate more widespread disease affecting multiple organ systems.

277 f abnormal protein glycosylation that affect multiple organ systems.

278 or studying the effects of hypothyroidism on multiple organ systems.

279 morphology at single-cell resolution within multiple organ systems.

280 d be expected to lead to disorders involving multiple organ systems.

281 postnatal survival and normal functioning of multiple organ systems.

282 spectrum of clinical presentations involving multiple organ systems.

283 nserved and involved in the morphogenesis of multiple organ systems.

284 , neuropathy, and metabolic abnormalities in multiple organ systems.

285 pread potential for hamartomatous growths in multiple organ systems.

286 iology, characterized by profound changes to multiple organ systems.

287 -related adverse reactions (irAEs) affecting multiple organ systems.

288 e-cigarettes impact vascular function across multiple organ systems.

289 e involving infiltration of myeloid cells in multiple organs, temperature reduction, weight loss and

290 ia (FRDA) is a progressive disease affecting multiple organs that is caused by systemic insufficiency

291 fic effects in development and physiology of multiple organs, thereby contributing to sexual dimorphi

292 sease that presents with rapidly progressive multiple organ thromboses.

293 ectural alteration and functional decline of multiple organs throughout an organism.

294 disease often result in severe compromise of multiple organs, tissue repair and organ function recove

295 We identified viral antigen in multiple organ tissues where it was not detected previou

296 lacenta targets the maternal endothelium and multiple organs to adjust metabolism for an optimal preg

297 adverse functional and structural changes in multiple organs which contribute to increased morbidity

298 these materials can image micrometastases in multiple organs with spatiotemporal resolution.

299 cates Msi1 in mouse postnatal development of multiple organs, with Notch signaling alterations contri

300 and mitochondrial DNA mutations that affect multiple organs, with the central and peripheral nervous